Study #2023-0409
Parallel RandOmized STudy of personalized Apalutamide treatment and evaluation to improve quality of life in postoperative radiation with Androgen Axis suppression. A phase III multi-center study for men with detectable PSA after prostatectomy for prostate cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Androgen Deprivation Therapy, Apalutamide
Description
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Study phase:
Phase III
Physician name:
Karen Hoffman
Department:
Radiation Oncology
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.